Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.74 |
| ▸ | PGR | P06401 | 5/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.74 |
| ▸ | AR | P10275 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | SHBG | P04278 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432443 | 1.00 | CYP3A4 (0.74) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL11696763 | 1.00 | CYP3A4 (0.74) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL372672 | 1.00 | CYP3A4 (0.74) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL8853780 | 1.00 | CYP3A4 (0.74) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL11694460 | 1.00 | CYP3A4 (0.74) | CYP3A4ABCB11PGRCYP2C19AR | |
| Norethindrone Acetate SCHEMBL8816427 | 0.97 | CYP3A4 (0.81) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL8853802 | 0.93 | CYP3A4 (0.79) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL8853605 | 0.89 | CYP3A4 (0.82) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL11694464 | 0.89 | PGR (0.62) | CYP3A4ABCB11PGRCYP2C19AR | |
| SCHEMBL11694468 | 0.89 | PGR (0.62) | CYP3A4ABCB11PGRCYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3852608-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2021-07-28 | — | — | EP | claimed |
| WO-2020061550-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | AUFBAU MEDICAL INNOVATIONS LIMITED (IE) | 2020-03-26 | — | — | WO | claimed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | claimed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | claimed |
| CN-105277633-B | A kind of defects inspecting analysis method of norethindrone derivative and its intermediate | 浙江仙琚制药股份有限公司 | 2017-06-23 | — | — | CN | claimed |
| US-20160089381-A1 | STABILITY OF PROGESTOGEN FORMULATIONS | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-31 | — | — | US | claimed |
| CN-105392469-A | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LTD | 2016-03-09 | — | — | CN | claimed |
| CN-105277633-A | Impurity detection analysis method of norethisterone derivatives and intermediates thereof | ZHEJIANG XIANJU PHARMACEUTICAL CO LTD | 2016-01-27 | — | — | CN | claimed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| US-RE36247-E | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | WOCO INVESTMENTS, LTD. (CA) | 1999-07-06 | — | — | US | claimed |
| US-5820878-A | PERSISTENTLY RELEASES ESTROGEN AND LUTEAL HORMONE; COMPRISINGELASTOMERS, BLOCK POLYMERS, CROTAMITON AND SOFTENING AGENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-10-13 | — | — | US | claimed |
| CN-1178465-A | Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premeno pausal women | SCHERING AG (DE) | 1998-04-08 | — | — | CN | claimed |
| WO-1998010293-A1 | METHOD OF SCREENING FOR SIDE EFFECTS OF ANTICONCEPTIVES OR ESTROGEN AND/OR PROGESTERONE REPLACEMENTS OR SUPPLEMENTS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1998-03-12 | — | — | WO | claimed |
| WO-1998003180-A2 | USE OF SEX STEROIDS FUNCTION MODULATORS TO TREAT WOUNDS AND FIBROTIC DISORDERS | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 1998-01-29 | — | — | WO | claimed |
| CN-1164187-A | Transdermal patch | HISAMITSU PHARMACEUTICAL CO (JP) | 1997-11-05 | — | — | CN | claimed |
| EP-0787488-A1 | PERCUTANEOUSLY ABSORBABLE PATCH | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1997-08-06 | — | — | EP | claimed |
| EP-0136011-B1 | A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor | PRE JAY HOLDINGS LTD (CA) | 1997-01-22 | — | — | EP | claimed |
| US-4826831-A | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | PRE JAY HOLDINGS LIMITED (CA) | 1989-05-02 | — | — | US | claimed |
| US-4181721-A | Depot preparations in an oily, unsaturated solution for intramuscular injection | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | CYP3A4 385/4885ABCB11 1106/4885PGR 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.